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A B S T R A C T
Background: amyloid-PET reading has been classically implemented as a binary assessment, although the clinical
experience has shown that the number of borderline cases is non negligible not only in epidemiological studies of
asymptomatic subjects but also in naturalistic groups of symptomatic patients attending memory clinics. In this
work we develop a model to compare and integrate visual reading with two independent semi-quantification
methods in order to obtain a tracer-independent multi-parametric evaluation.
Methods: We retrospectively enrolled three cohorts of cognitively impaired patients submitted to 18F-florbetaben
(53 subjects), 18F-flutemetamol (62 subjects), 18F-florbetapir (60 subjects) PET/CT respectively, in 6 European
centres belonging to the EADC. The 175 scans were visually classified as positive/negative following approved
criteria and further classified with a 5-step grading as negative, mild negative, borderline, mild positive, positive
by 5 independent readers, blind to clinical data. Scan quality was also visually assessed and recorded. Semi-
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quantification was based on two quantifiers: the standardized uptake value (SUVr) and the ELBA method. We
used a sigmoid model to relate the grading with the quantifiers.
We measured the readers accord and inconsistencies in the visual assessment as well as the relationship
between discrepancies on the grading and semi-quantifications.
Conclusion: It is possible to construct a map between different tracers and different quantification methods
without resorting to ad-hoc acquired cases. We used a 5-level visual scale which, together with a mathematical
model, delivered cut-offs and transition regions on tracers that are (largely) independent from the population.
All fluorinated tracers appeared to have the same contrast and discrimination ability with respect to the ne-
gative-to-positive grading. We validated the integration of both visual reading and different quantifiers in a more
robust framework thus bridging the gap between a binary and a user-independent continuous scale.
1. Introduction
Assessment of brain Aβ amyloidosis has gained a pivotal role in the
diagnosis of Alzheimer's disease (AD) in vivo, according to the last
National Institute of Aging-Alzheimer Association (NIA-AA) (McKhann
et al., 2011, Albert et al., 2011) and the International Working Group-2
(IWG-2) criteria (Dubois et al., 2014). Moreover, the 2018 research
framework identifies a stage of Alzheimer pathology for isolated brain
amyloidosis while the term AD is reserved to the concomitant amyloid
and tau pathology (Jack Jr et al., 2018). The concordance between CSF
Aβ42 levels and amyloid load on PET is good (over 80%; Hansson et al.,
2018) although data shows that CSF Aβ levels changes may precede
brain amyloid deposition and thus it should be considered as an earlier
phenomenon (Palmqvist, 2016). Instead, brain amyloid load on PET
still continues to increase even after the onset of cognitive symptoms
(Farrell et al., 2017). Moreover, the availability of Aβ40 assays has
shown that a non-trivial part of patients are high or low Aβ amyloid
producers so that the Aβ42/40 ratio better reflects the real amyloidosis
status of a subject and allows better correlation with amyloid load on
PET (Niemantsverdriet et al., 2017).
The amyloid PET reading has been classically implemented as a
binary lecture, i.e., negative or positive for amyloidosis, however the
current clinical experience has shown that the number of borderline
cases is not trivial not only in epidemiological studies in asymptomatic
subjects but also in naturalistic groups of symptomatic patients at-
tending a memory clinic to receive a diagnosis (Payoux et al., 2015).
This behaviour actually mirrors what happens with CSF Aβ assay
showing a non-negligible borderzone around the cut-off value identi-
fying positive and negative subjects (Molinuevo et al., 2014).
The APOE genotype (presence of at least one epsilon-4 allele) is a
major determinant of the degree of amyloidosis (Drzezga et al., 2009)
but other, less known factors may play a role (Wang et al., 2017). In any
case, the binary lecture is poorly adequate to address the clinical reality
and complexity and, even within the two extreme classes – i.e. negative
or positive – there is inhomogeneity because there are subjects that are
more or less positive and those who are more or less negative (Fleisher
et al., 2011). Taking together all this information, brain amyloidosis
across subjects attending a memory clinics appears more as a con-
tinuum rather than a clusterized, binomial distribution.
Therefore, the issue arises on how to quantify and grade such a
continuum, whether the continuum with a specific fluorinated radio-
pharmaceutical is similar to the one obtained with the other two
available fluorinated radiopharmaceuticals, and how to share this in-
formation among labs. The so-called “centiloid project” (Klunk et al.,
2015) has tried to give an answer to this issue and is certainly of value
but it requires that each center builds-up its own cohort of normal
subjects in different age ranges. Moreover, it is based on SUVr com-
putation that certainly has advantages but also disadvantages, such as
the uncertainty about the reference region and on how to draw the
cortical ROIs.
In the present study and in the frame of the PET study group of the
European Alzheimer's disease Consortium (EADC) we aim at: (a) pro-
pose and validate a method to compare semi-quantification values
among tracers regardless of the semi-quantification approach (SUVr-
based or SUVr-independent); (b) define transition regions and cut-off
values which are (largely) independent from the cohorts; (c) test a more




The amyloid PET project of the EADC (PET 2.0 [1]) is aimed at
joining together amyloid PET scans with corresponding clinical and
neuropsychological data from subjects attending a memory clinic of one
of the EADC centers.
To the purpose of this project, both subjects with a positive or ne-
gative amyloid PET scan according to visual dichotomic evaluation, as
established by the local nuclear medicine physician, were enrolled.
We identified the fluorinated tracer with the lowest number of scans
available (i.e., 18F-florbetaben, 53 subjects) and then a similar number
of subjects with the other two fluorinated tracers (18F-flutemetamol, 62
subjects; 18F-florbetapir, 60 subjects). Only with the 18F-florbetapir we
randomly sampled the database in order to maintain the highest pos-
sible number of centers overlapping with the other two tracers, and to
maintain an approximate balance in number of cases per center. These
subjects constitute three cohorts, one per each tracer. The selection was
done from some of those EADC centers participating to the PET 2.0
project, namely: Genoa (GEN), Brescia (BRE), Geneva (HUG), Antwerp
(ANT), Paris (PAR), and Mannheim (MAN) according to scan avail-
ability on the tracer of choice. Subjects main demographics and clinical
characteristics are summarized in Table 1.
Subjects received a diagnosis after the first diagnostic work-up, in-
cluding the result of amyloid PET scan, and were followed-up clinically
for an average time of 30.1 [6–143] months. We considered the diag-
nosis as clinically confirmed at the last available visit. The selected
subjects were diagnosed as affected by mild cognitive impairment
(MCI) due to AD (MCIAD), probable (prob) or possible (poss) AD de-
mentia, frontotemporal dementia (FTD), dementia with Lewy bodies
(DLB), or vascular dementia (VaD) according to current criteria
(McKhann et al., 2011; Albert et al., 2011; Rascovsky et al., 2011;
McKeith et al., 2005; Gorelick et al., 2011). Moreover, those subjects
who did not received a definite pathogenetic diagnosis were still la-
beled as affected by amnestic (aMCI) or non-amnestic (naMCI) MCI.
The population also included some subjects with the so called ‘pseu-
dodementia’ (pseudoDD, that is, psychiatric conditions that can mimic
dementia), or with subjective cognitive complaints but without evi-
dence of deficit on neuropsychological tests (SCI).
The study was approved by the local Ethics Committees and all the
recruited subjects provided an informed consent.
1 “EADC-PET 2.0 project (Disease Markers).” http://www.eadc.info/sito/
pagine/c_09.php?nav=c. Accessed 17 Oct. 2018.
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2.2. PET acquisition
Amyloid PET acquisition followed the recommendations of tracer
manufacturers and the joint guidelines of the European Association of
Nuclear Medicine and the Society of Nuclear Medicine (Minoshima
et al., 2016). The equipment used was a PET-CT tomograph and is listed
in Table 1 for each center. Three-dimensional static scan acquisition
was performed in all centers, and attenuation correction was based on
CT. Image reconstruction was made with Ordered Subset-Expectation
Maximization algorithm following the standard brain protocols em-
bedded in each equipment. Each center was responsible for sending
good-quality data but a further quality check was performed by the core
center in Genoa. In order to reproduce the clinical situation in the real
world, only unreadable scans were rejected while all other scans were
submitted to further analysis.
2.3. CT subset
A subset of all cohorts – 50% in total: 39 subjects with flutemetamol,
29 with florbetaben and 20 with florbetapir – came with the companion
CT scans. While all PET scans were read without CT, the subset with the
CT underwent a separate, further evaluation following the same rules
detailed in Visual Evaluation. The intent is to use this subset to validate
the statistics of evaluation and accord among readers even when the
assessment was conducted without the CT.
2.4. Visual evaluation
The 175 scans were independently presented to five readers, in-
cluding three expert (UPG, FN and VG) and two intermediate-expert
readers (AC and MB). The three experts passed the training qualifica-
tion of the three vendors and are used to report several scans monthly
since the time of availability on the market of the radio-
pharmaceuticals, always with the agreement of at least another expert
and with the assistance of semi-quantification based on both SUVr and
SUVr-independent tools (Chincarini et al., 2016). The two intermediate-
expert readers share the same characteristics as the experts but are
reading scans for a shorter time.
The anonymized scans were presented in the native space, rando-
mized, and the reader was blind to the clinical information and the
reading of the other experts. No MRI or CT scans were provided to-
gether with PET scans (see also CT subset comparison).
Readers were asked three questions as follows:
A. quality flag: a dichotomous response on sub-optimal scans. There is
no formal or shared definition on scan quality. This flag was raised
according to each reader own's experience. Typically though sub-
optimal quality involves image acquisition flaws like field of view
cuts or poor count rate; it can also be related to image reconstruc-
tion issues like excess smooth, artefacts, etc.
B. binary evaluation: negative/positive according to the approved in-
dications of each manufacturer.
C. 5-step evaluation: visual grading into classes: {negative, mild ne-
gative, borderline, mild positive, positive} according to Paghera
et al., 2019 (see below).
Readers were presented with 3 batches (flutemetamol, florbetaben,
florbetapir) and they were informed of the tracers used.
The evaluation of each batch was completed sequentially, with at
least 2 weeks time between one batch and the next. After the three
evaluation batches, the CT subset was sent to the readers to get a new
independent evaluation with the help of the companion CT.
2.5. Semi-quantification methods
The visual assessment of the amyloid PET scan is a non-trivial task
that is often complemented by measures derived from semi-quantifi-
cation methods (hereafter named quantifiers). These measures are in-
tended to be proxies of the brain amyloid load.
Among quantifiers, the Standardized Uptake Value ratio (SUVr)
(Kinahan and Fletcher, 2010) is the most widely used and validated,
compared to the binary reading.
This approach calculates the ratio of PET counts between a target
region of interest (ROI) versus a reference one. In this study the SUVr
was estimated using the whole cerebellum as reference region. As re-
ported in the literature (Schmidt 2015), this choice makes the measure
less prone to segmentation errors than the selection of the cerebellum
gray matter or the brain stem. The SUVr score was calculated as the
average cortico-cerebellar SUVr on all scans. Similarly to what ac-
complished in (Klunk et al., 2015), the target cortical ROI included the
medial frontal gyrus, the lateral frontal cortex (middle frontal gyrus),
the lateral temporal cortex (middle temporal gyrus), the lateral parietal
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Age [y] 69.7 62.3 60.3 72.6 66.2 69.2 72.5 72.0 77.5 71.0
[54 79] [42 78] [45 70] [55 82] [48 84] [51 71]] [59 80] [60 84] [68 85] [59 83]
Sex (M %) 46.7 40.0 49.1 60.0 56.7 30.0 51.9 45.0 16.7 45.8
MMSE score 26.7 27.9 28.2 27.7 24.6 27.1 26.1 22.1 25.1 27.6
[18 30] [24 30] [25 30] [24 30] [14 30] [2030] [15 30] [13 28] [15 30] [1330]
MCIAD (%) 24.1 41.5 23.1
possAD (%) 1.6 3.4
probAD (%) 4.8 18.8 15.0
probFTD (%) 1.6 3.8 3.2
possFTD (%) 4.8 3.4
possDLB (%) 1.6
probVaD (%) 1.5
PseudoDD (%) 1.6 13.2 10.0
aMCI (%) 14.6 3.8 8.2
naMCI (%) 32.2 9.4 6.5
SCI (%) 13.0 9.4 25.7
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The other quantifier used in this study is named ELBA (Chincarini
et al., 2016). It is a SUVr-independent approach that is designed to
capture intensity distribution patterns rather than actual counts in
predefined ROIs. These patterns are global properties of the whole brain
and do not require a reference ROI. ELBA showed good performance
versus the visual classification, highly significant correlation with the
result of CSF Aβ42 assay, and has ranking characteristics proven both
on cross-sectional and longitudinal analyses (Chincarini et al., 2016).
Similarly to the procedure described in (Chincarini et al., 2016),
quantifiers were applied onto the spatially-normalized image. Briefly,
the procedure mapped the PET onto the T1-weighted MRI template in
MNI space (with isotropic spacing and voxel dimension of 1x1x1 mm)
with a registration consististing in: global intensity re-scaling, rigid
registration, affine registration. Then, a pre-segmented atlas which in-
cluded cortical and cerebellar ROIs was mapped from the MNI space to
the affine-transformed PET with a deformable registration. We used the
ANTs registration software (Avants et al., 2011) with the mutual in-
formation metric.
Both quantifiers were implemented in an automatic analysis pro-
cedure that did not require any human supervision with the exception
of an visual check after the spatial normalization process onto the MNI
space.
2.6. Analysis
2.6.1. Sample homogeneity and data model
Direct comparison of semi-quantification values over different tra-
cers is possible in principle, if one is in possess of a set of subjects who
have been acquired with two or more tracers over a reasonably short
time frame (i.e. with respect to the typical physiological change in
amyloid deposition). Alternatively, one could use statistically equiva-
lent reference cohorts. This latter approach is the one followed by the
centiloid method, where the ad-hoc acquisition of a group of young
healthy controls and a group of confirmed AD subjects – both analyzed
with the quantification method of choice – constitutes the centiloid
scale references.
Unfortunately our three cohorts are not statistically equivalent
(both in sample size, center distribution and clinical evaluation) and
neither can they be considered scale extremes, so that direct compar-
ison among semi-quantification values cannot be applied.
Given that the visual reading is the de-facto gold standard in as-
sessing positivity in a clinical setting, we can exploit it as cross-tracer
comparison method. A model is therefore necessary to link the visual
assessment to the semi-quantification. The binary reading is though too
coarse to provide a meaningful relationship, we therefore resort to the
grading.
Positivity grades have been conventionally declined into numbers
ranging from 1 to 5 (negative → mild negative → borderline → mild
positive → positive). Basic considerations on the transition continuity
and on the floor/ceiling effect on negative/ positive evaluations suggest
that a possible model of the grading versus semi-quantification is a







S q s o
1 exp[ ( )]
( , , )
where ‘g’ is the grading, ‘p’ and ‘n’ are the numerical equivalent of the
positive and negative gradings, ‘q’ is the quantification value, ‘s’ is the
slope and ‘o’ is the offset.
For each tracer, the sigmoid function of our model has only 2 free
parameters: the slope ‘s’ and the offset ‘o’. All other parameters are set
by the limit grading values (negative for quant. score → -∞, positive for
quant. score → ∞). This ensures that the models are (largely) in-
dependent from the sample characteristics because of the few degrees of
freedom versus the sample size (~60 scan in each cohort).
Models are used in synergy with visual grading to provide a map-
ping between tracers.
2.6.2. Readers concordance
Readers evaluated all scans independently. We can therefore assume
that their errors are uncorrelated and that their mean is a good esti-
mator of the “true” evaluation. While this holds true for a large number
of measures, we need to ensure that the error on the mean is relatively
small even when employing 5 readers only. This assumption is accep-
table if the accord among readers is sufficiently high.
To assess reader concordance we compute the intra-class correlation
coefficient (ICC, two way random-effect model, mean of k raters) for
the whole dataset and on the single cohorts (one per tracer, Table 3).
Between each reader we also compute the Cohen k.
For each tracer and for each reader we compute the grades statistics,
i.e. the number scans in each grade (Table 2).
Table 2
Evaluation fraction by grade.
Reader negative (%) mild neg (%) borderline (%) mild pos (%) positive (%)
All tracers UPG 23 14 5 22 36
FN 25 10 9 17 39
AC 17 18 21 19 26
VG 11 22 9 19 38
MB 22 21 10 14 33
All 19.6 17 10.8 18.2 34.4
Flutemetamol UPG 15 23 8 32 23
FN 23 10 15 19 34
AC 8 16 35 18 23
VG 6 24 13 24 32
MB 23 26 11 18 23
All 15 19.8 16.4 22.2 27
florbetaben UPG 25 9 2 13 51
FN 23 13 2 11 51
AC 21 11 6 17 45
VG 19 15 4 17 45
MB 23 15 8 13 42
All 22.2 12.6 4.4 14.2 46.8
florbetapir UPG 30 10 5 18 37
FN 30 7 8 20 35
AC 22 25 18 23 12
VG 10 27 8 17 38
MB 20 22 10 12 37
All 22.4 18.2 9.8 18 31.8
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The between tracer distribution is also visually shown with a
heatmap (number of scans per each grade pairs) and the Bland-Altmann
plot (Fig. 7 in Supplementary materials).
2.6.3. Visual assessment and semi-quantification
The relationship between visual grading and quantification is found
by fitting the sigmoid model onto the data. Model parameters are fit
both onto z-score quantifier values (direct model, grading vs. quanti-
fiers) and on the raw quantifiers data (inverse model, quantifiers vs.
grading).
In the direct model, each scan is identified by the z-scored value of
the quantifier (either ELBA or SUVr) and by its average grading. z-
scores are computed on each cohort separately.
With the z-scores model we can easily visualize relationships with
the two quantifiers on the same plot and we can evaluate potential
significant differences, both between quantifiers and among tracers.
We use the fitted models to define a transition region (from mild-
negative to mild-positive) and the cut-off on all tracers. These quantities
are found at the intersection of the models with the mild-negative,
borderline and mild-positive coordinates on the y-axis (Fig. 1).
Both the transition region and the cut-off values depend on the data
only through the model, so they can be considered a proxy of cohort-
independent definitions.
Given their good correlation (see Fig. 3), the two z-scored
Fig. 1. Quantification-visual assessment relationship for the 3 fluorinated tracers. On the x-axis: z-score of the two quantifiers; on the y-axis the average visual
grading. Dots represents scans, continuous line is the sigmoid model. Intersection of model with mild and borderline evaluations is projected onto the scores to define
a transition region (gray area) and the cutoff (gray line).
A. Chincarini, et al. NeuroImage: Clinical 23 (2019) 101846
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quantifiers can be further summarized into a single value, that is the
score on the first PCA axis (PCA1). This allows us to abstract the
quantification (potentially including more than two quantifiers) and
focus on the relationship with the gradings.
While the direct model is useful for comparison and visualization,
the inverse model is used to estimate the between-tracers mapping.
2.6.4. Evaluation latitude
We grouped scans according to similar average grading. Groups may
contain one or more scans. Each group is assigned a quantification
value, which is the average score of its members onto the PCA1.
Each group is also assigned an “evaluation latitude”; with this term
we intend the overall scope of gradings, that is, the largest span of
evaluations given by all readers on a scan or group of scans. The group
evaluation latitude is therefore a range, spanning the lowest to highest
grading received on any of the group's member.
The relationship between group's score and latitude provides further
information on the reading discrepancies as function of the quantifi-
cation (Fig. 2).
2.6.5. Binary assessment
Each reader assigned a binary visual assessment – negative (n)/
positive (p) – to the scan, according to each tracer's standard evaluation
rules. With 5 independent readers we have therefore 6 possible classes:
Fig. 2. Relationship between quantification score and evaluation latitude. Each circle represents a group of scans sharing the same average grading. The group
position on the x-axis is the average score of its members on the first PCA axis (PCA computed on the z-score quantifiers). The group position in the y-axis is the
average grading. Vertical lines show the group evaluation latitude, that is, the lowest to highest grading received on any of the group's member.
A. Chincarini, et al. NeuroImage: Clinical 23 (2019) 101846
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5n-0p, 4n-1p … 0n-5p. We explored the distribution of the binary
reading on a scatter-plot which also shows the relationship between the
quantifiers.
We used the cut-off and the transition regions derived from the
model (section Visual assessment and semi-quantification) to compute
accuracies for both quantifiers. In this latter analysis we considered
negative scans as belonging to classes {5n-0p, 4n-1p, 3n-2p} and po-
sitive scans as belonging to classes {2n-3p, 1n-4p, 0n-5p} (Fig. 3).
The reader accord on the binary assessment is shown with the
Cohen k, to be compared to the grading (Tables 4 and 7).
Then, we looked at possible relationships between the binary
reading and the discrepancies on the grading (latitude). For each scan
we assigned the binary class (among the 6 possible choices) and we
computed the latitude, i.e. the maximum grading difference among
those received. We then counted how many scans are there per class
and latitude (Fig. 4).
2.6.6. Scan quality effect
The third type of visual assessment is the scan quality. This is simply
a flag indicating whether acquisition nuisance and/or reconstruction
procedures would result in a sub-optimal image, according to each
reader's own experience.
We study whether scan quality has any relationship with quantifi-
cation and evaluation latitude.
First we plot the number of quality flag versus the second PCA
components (PCA2). The PCA1 encodes the quantification (negative to
positive), while the PCA2 mainly encodes discrepancies between the
quantifiers (approximately off-diagonal distances in the ELBA-SUVr
scatter plots, Fig. 3). We then look at biases in the quality distribution.
Then, we compute the matrix of the number of quality flags for each
scan grouped by the latitude (i.e. the grading range).
2.6.7. CT subset comparison
Finally we compare evaluations on the subset with companion CT.
Comparison between evaluations with/without CT is carried out by
testing χ2 statistics on the 5-step grading and binary distribution, and
by comparing the intra-rater ICC and Cohen's k.
2.6.8. Mapping
We have now all the tools to map quantifications on one tracer into
another. While the direct model ‘S' maps z-scored quantifier values into
gradings, the inverse model ‘S−1′ maps the gradings into the raw
quantification values. If we keep the visual gradings as constants across
tracers, we can bind two models together (model mapping).
Mathematically, this means that for each tracer pair ‘i-j’ we have a
set of two equations for the inverse model S−1, with model parameters s
(slope) and o (offset, see Table 6):
=
−q S g s o( , , )i i i1
=
−q S g s o( , , )j j j1
These represent the expected (i.e. modeled) quantifier value q of the
i-th and j-th tracer calculated in the grading coordinate g. As g ranges in
[1..5], we therefore have a vector of 5 quantifier coordinates [qi, qj].
These coordinates are linearly regressed to find the mapping functions
listed in Table 9.
Another possible and distinct approach is to consider visual grading
ranges as containers, in order to group subjects into comparable sets;
that is, we might consider as equivalent two sets from different tracer
cohorts, whose subjects received a mean average grading between – say
– negative and mild negative. Container classes would therefore be 4:
negative to mild negative, mild negative to borderline, borderline to
mild positive, mild positive to positive. This latter approach is similar to
the centiloid one, as it aims at constructing a series of comparable
groups across tracers cohorts, thus avoiding the need for a model. In
principle, albeit with a much higher number of scans, we could detect
Fig. 3. ELBA-SUVr scatter-plot with binary visual assessment. Dots represent
scans, colors are according to the combination of negative and positive eva-
luations given by the 5 readers.
A. Chincarini, et al. NeuroImage: Clinical 23 (2019) 101846
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deviations of the mapping from a linear dependence, a possibility that is
lacking in the centiloid method.
The linear regression over container cohorts is done on the average
quantifier values and takes into account standard deviations on both
quantifiers according to York et al., 2004.
While we are plagued by the relatively small number of subjects in
some of the intermediate container classes, we still use this approach to
cross-check the model mapping. We therefore require that the model
mapping be compatible with the (linear) regression computed on con-
tainer classes.
2.6.9. Validation
Last analysis is a validation of the mapping model. We run a
MonteCarlo simulation to construct populations sharing the same
grading distribution. For instance, we first select a reference cohort A –
say the florbetaben scans – and another test cohort B – say the flute-
metamol scans. The visual grading distributions of cohorts A and B are
typically statistically different (Kolmogorov-Smirnov test p-value<
.05). We now resample cohort B with appropriate weights (and with
repetition), in order to create a new cohort B′ whose grading distribu-
tion is statistically equivalent to the cohort A.
If we look at the distribution of quantification values of the two
cohorts A and B′ (either with ELBA or with SUVr) we still find these
distributions statistically different because of the different tracers (i.e.
quantifiers values are expressed in their own tracer units). We show
that when we apply the model mapping we can nullify the statistical
differences between A and B′.
In essence, population resampling plus model mapping give statis-




The statistics on the grading evaluations is summarized in Table 2.
The general overall assessment of accord among readers on the grading
is measured by the ICC (two way random-effect model, mean of k
raters, absolute agreement, Table 3). The agreement is very good
(> 95%) both on the whole dataset and on the single cohorts. ICC on
Florbetaben is higher due to the relative lack of borderline cases in the
graded evaluation (higher rate of AD-like diagnosis, Table 1).
The Cohen k for agreement between pairs of reviewers ranged from
0.39 to 0.49 (fair agreement, Table 4).Overall, the borderline scans
were 10.8% (a non-trivial amount) whereas in the 35.2% of cases the
readers defined the scan ‘mildly’ positive or negative.
A more detailed comparison among raters is shown in Fig. 7 (sup-
plementary materials): this plot summarizes statistics and between
readers agreement grouped by the 5 gradings. The heatmap re-
presentation – where color intensity is proportional to the number of
scans – shows where discrepancies are more likely to occur. Besides the
Fig. 4. Relationship between the binary evaluation and the latitude. Each box shows the number of scans grouped by binary class and maximum grading difference
received in the 5-step visual assessment.
Table 3
ICC Two way random-effect model, mean of k raters (ab-
solute agreement).
Tracer ICC [95% CL]
Flutemetamol 0.952 [0.93 0.969]
Florbetaben 0.987 [0.98 0.992]
Florbetapir 0.959 [0.94 0.974]
All tracers 0.967 [0.96 0.975]
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transition region, which is an obvious candidate, severe deviations from
the diagonal (i.e. Δ grade > 2) can occur on all grades, albeit on very
few scans.
Finally, we show the number of discrepancies grouped by severity in
Table 5.
3.2. Visual assessment and semi-quantification
The model-mediated relationship between the grading and the
quantifiers is shown in Fig. 1. There is no significant difference among
models (z-score), both with respect to quantifiers and with respect to
tracers (direct model, Table 6).
The transition region width is very similar among tracers, showing
that there is no substantial difference in assessing the negative/positive
contrast both with different tracers and with different quantifiers. For
instance, the ELBA transition region width (in z-score units) is 0.64,
0.66 and 0.67 for flutemetamol, florbetaben and florbetapir respec-
tively. These numbers are all compatible when we consider the para-
meters uncertainty.
3.3. Evaluation latitude
We now group subjects by average evaluation and we plot them
versus their mean quantification value (here the score on the PCA1). We
can graphically represent the group's latitude by means of a line that
spans the lowest and highest evaluation received by any member of the
group (Fig. 2). We can glance at the latitude distribution and see that it
tends to cluster in the mild negative to borderline region.
3.4. Binary assessment
Reader agreement is ranked according to Cohen k (Table 7) and
values ranges from 0.71 to 0.84 (substantial agreement). Accuracies
based on binary semi-quantification (i.e. above/below cutoff) are re-
ported in Table 8.
The distribution of the binary reading is shown on the quantifier
scatter-plot in Fig. 3. We see that pure classes {5n-0p, 0n-5p} nicely
cluster in the lower-left and upper right quadrant respectively, whereas
intermediate classes (particularly {2n-3p, 3n-2p}) tend to aggregate
near both transition regions.
Gray areas and gray lines are the transition regions and cut-off va-
lues derived from the intersection of the models with the mild-negative
/ borderline / mild-positive coordinates.
3.5. Scan quality effect
The distribution of quality flags is shown on all tracers together
versus the two PCA components computed on the quantifiers (Fig. 5
left). There is a marked bias toward negative-to-borderline scans while
there seems to be no relation with respect to quantifiers discrepancy
(PCA2 axis).
Comparing quality to latitude, one would expect a positive trend
linking the number of quality flags and the assessment discrepancies.
Results shows that the latitude is substantially independent on the
quality, hinting to a solid performance and coping ability of the trained
eye (Fig. 5 right).
3.6. CT subset
We compute the intra-rater statistics on the assessments with and
without the CT (88 scans, ~50% of the whole dataset).
χ2 statistics was calculated on all tracers and for each reader on both
the grading and the binary frequencies. No significant difference was
found on the grading (for all readers, χ2 < 4.72, p-value> .35) and on
the binary evaluation (χ2 < 0.75, p-value> .38).
The ICC on the grading, for all raters and on the whole CT dataset, is
0.982 [0.980–0.987].
The Cohen's k, computed on the grading and per rater, is: k=0.65,
0.84, 0.76, 0.78, 0.85 for UPG, FN, AC, VG, and MB respectively.
We conclude therefore that there is no significant difference in the
evaluation statistics when the CT is present.
3.7. Mapping and validation
The complete set mapping functions between one tracer to another
is shown in Fig. 6.
The mapping function looks linear because of the substantial
equivalence between model parameters (see Table 6). We can then
easily convert any value from one tracer's own units into another (in
particular the cut-off and the transition region), as detailed in Table 9.
Similarly we can use cohort containers (i.e. grouping subjects by
average visual assessment lying between two adjacent gradings) to fit a
linear regression. The cohort container regression does not require the
sigmoid model and relies on the visual assessment only modestly, as we
are fitting the average container values. Results show that the model
fitting is well within the container regression error (see Table 10 in the
supplementary materials).
4. Discussion
We have shown that it is possible to construct a map between dif-
ferent tracers and different quantification methods without resorting to
ad-hoc acquired cases, as required in the centiloid approach or in stu-
dies where the same subjects are injected with more tracers.
In doing this we, used a 5-level visual scale, to define cut-offs and
transition regions on tracers in a way largely independent from the
population.
The link between the graded visual scale and semi-quantification is
the sigmoid model. The use of the sigmoid function simply derives from
the considerations that the amyloid load is a biologically continuous
process with two boundaries (i.e. saturation at both the decidedly ne-
gative and positive range), which naturally translates in a smooth (i.e.
infinitely derivable) function with finite limits and a near-linear re-
sponse in the transition.
Obviously, other functional models could do, and possibly with
more data one could appreciate the asymmetry already partially visible
in these data when transitioning from negative-to-borderline with re-
spect to the borderline-to-positive.
The integration of model and grading allows to compare semi-
quantification values regardless of the approach (either SUVr-based or
Table 4
Agreement between pairs of readers all tracers with respect to the grading
evaluation using accuracy and Cohen k (within brackets).
UPG FN AC VG MB
UPG 0.61 (0.48) 0.55 (0.44) 0.59 (0.46) 0.61 (0.49)
FN 0.61 (0.48) 0.60 (0.49) 0.62 (0.49) 0.62 (0.50)
AC 0.55 (0.44) 0.60 (0.49) 0.58 (0.46) 0.55 (0.43)
VG 0.59 (0.46) 0.62 (0.49) 0.58 (0.46) 0.53 (0.39)
MB 0.61 (0.49) 0.62 (0.50) 0.55 (0.43) 0.53 (0.39)
Table 5
number of scans with minor (Δ grade ± 1), mild (Δ grade ± 2) and severe
discrepancies (Δ grade > 2).
tracer no discrepancy minor mild severe
flutemetamol 19 21 16 6
florbetaben 26 22 5 0
florbetapir 8 29 20 3
all tracers 53 72 41 9
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SUVr-independent) and employed tracer. This combination (a) defines
transition regions and cut-off values; (b) indirectly confirms the ap-
propriateness of a visual evaluation scale which is more apt to re-
cognize transitions (similarly to several other clinical and visual scales
(Scheltens et al., 1992)).
As models have only two free parameters, derived quantities (cut-
off, transition region) are more robust with respect to the sample size
and can be easily generalized.
The width of the transition region and the substantial similarity of
the sigmoid models show that no tracer is the winner here, all are
equivalently discriminating (i.e. no slope difference implies equivalent
contrast). While to our knowledge there is no literature on tracers
comparison within the same dataset and with the evaluation from the
same set of readers, we can compare this result to Curtis et al. (Curtis
et al., 2015), where the accuracy of all three fluorinated tracers in the
phase-3 study is compared and similar conclusions are drawn. Im-
portantly, the determination of a threshold for abnormality common
across tracers is one of the required validation steps for the use of
amyloid PET in AD following a recently proposed roadmap for bio-
markers for an early diagnosis (Frisoni et al., 2017, Chiotis et al., 2017).
As a by-product of the work, we have studied the relationship be-
tween concordance and discordance of readers according to some in-
dicators such as the degree of negativity / positivity, the quality of the
scan and the binary evaluation.
On the reader concordance, first we notice a very good agreement
among readers in binary lecture, accuracy ranging from 86% to 94%,
meaning that in routine clinical practice only about one out of ten scans
might be read with opposite conclusions. If on the one hand the present
experimental setting does not fully reproduce the clinical reality where
a doubtful scan is usually evaluated together by more than one reader
and sometimes with the aid of semi-quantification tools (while here the
raters were blind), on the other hand our raters were high to inter-
mediate experts thus likely more skilled than the average of the real
world. However, this figure is in keeping with other studies (Collij
et al., 2019; Nayate et al., 2015) – if not higher – and points to the need
of semi-quantification tools in assisting the nuclear medicine physician
in the binary interpretation of scans.
In more details, when we look at the grading we see that while the
overall observed ICC was very good, the discrepancies in the mild-ne-
gative / borderline regions (latitude) are rather significant. That is,
despite the differences in expertise among readers and the multi-centre
nature of the study, the learning curve for visual amyloid PET readings
is not steep after a moderate degree of expertise has been acquired; on
the other hand, evaluation errors are not evenly distributed across the
positivity spectrum.
Considering the three tracers altogether we observed a ‘U’-shape
distribution with higher percentage at the two extremes and progres-
sively lower percentages toward the borderline cases (see Fig. 7 in
supplementary materials). With individual tracers this pattern was less
evident with flutemetamol disclosing a higher percentage in mild ne-
gative than in negative subjects while it was stronger with florbetaben.
This mismatch could be due to the higher prevalence of subjects with
Table 6
Model parameters.
Tracer Quantifier Slope Offset
Raw values (inverse model, quantifier vs. grading)
Flutemetamol SUVr −10.05 [−10.84 –9.26] 1.11 [1.04 1.18]
ELBA −13.41 [−14.54 –12.28] 0.76 [0.72 0.79]
Florbetaben SUVr −7.71 [−8.01 −7.41] 1.23 [1.17 1.29]
ELBA −9.65 [−10.06 –9.24] 0.85 [0.82 0.89]
Florbetapir SUVr −16.97 [−18.70 –15.24] 1.16 [1.11 1.21]
ELBA −11.40 [−12.00 –10.80] 0.87 [0.84 0.90]
z-score values (direct model, grading vs. quantifier)
Flutemetamol SUVr 3.80 [2.91 4.70] −0.27 [−0.53 −0.00]
ELBA 3.37 [2.57 4.17] −0.17 [−0.51 0.17]
Florbetaben SUVr 3.60 [3.01 4.19] −0.29 [−0.54 −0.03]
ELBA 3.54 [3.01 4.07] −0.26 [−0.50 −0.02]
Florbetapir SUVr 3.27 [2.39 4.15] −0.10 [−0.40 0.21]
ELBA 3.32 [2.79 3.84] −0.16 [−0.40 0.09]
Table 7
Agreement between pairs of readers on all tracers with respect to the binary
evaluation using accuracy and Cohen k (within brackets).
UPG FN AC VG MB
UPG 0.90 (0.80) 0.91 (0.81) 0.89 (0.76) 0.86 (0.71)
FN 0.90 (0.80) 0.91 (0.82) 0.93 (0.84) 0.86 (0.72)
AC 0.91 (0.81) 0.91 (0.82) 0.90 (0.79) 0.86 (0.71)
VG 0.89 (0.76) 0.93 (0.84) 0.90 (0.79) 0.87 (0.74)







Weighted average 0.87 0.89
Fig. 5. Left: distribution of the quality flags in the PCA plane; dots represents all scans, color is proportional to the number of quality issues raised by the 5 readers;
marginal distribution shows the kernel density estimation. Right: heatmap of quality and latitude, showing the fraction of scans normalized on the quality and the
actual number of scans sharing the same quality interpretation and evaluation latitude (within brackets).
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AD and with non-AD conditions as compared to the flutemetamol co-
hort (Table 1).
As remark on the evaluations with and without the CT information,
we first remind that readers have been trained to read amyloid PET
scans as taken alone, leaving the use of CT/MRI only in doubtful cases,
as per approved courses administered by pharmaceutical companies on
the respective products; second, readers are all rather experienced;
third, evaluation results with and without CT scans are not identical but
simply statistically equivalent. This latter statement meaning that there
were indeed patients whose evaluation was changed because of the CT
information, but the cohort statistical distribution was not significantly
altered.
We have to say we used data collected during clinical routine from
sparse European centers and thus carrying inhomogeneity in scan
quality and characteristics of patients. If this may have generated high
variability among scans, it is however the reality collected in natur-
alistic cohorts and thus closer to the real world with respect to the
setting of clinical trials.
Inhomogeneities are also evident when looking at latitude scans,
where the apparent different relationship with the tracers can be as-
cribed to the diversity of cohort provenance and statistics.
Interestingly, however, we failed to find a correlation between scan
quality and latitude (i.e., degree of differences among readers). This
may mean that the intrinsic subjectivity in human eye when reading an
amyloid PET scan is higher than quality inhomogeneity among scans.
This represents a distinct source of disagreement among readers that
adds to the one possibly deriving from low quality (Schmidt 2015).
Coming to the not-clearly positive/negative scans, we observed that
almost half (i.e., 46%) of scans were visually rated either as borderline
(10.8%) or mildly negative/positive (35.2%). Thus, the amount of
transitional patients is considerable even in the clinical setting facing
Fig. 6. Matrix plot of all between-tracers models and container-cohort fits. Dots represent the average quantification on the cohort containers, lines crossing the dots
are the standard deviations. The thick line is the model mapping, the dashed thin line is the linear regression based on the average quantification values (container
mapping). Cut-offs are based on the model mapping.
Table 9
conversion parameters between tracers (model mapping).
From/to Flutemetamol Florbetaben Florbetapir
ELBA
Flutemetamol 1.39 x – 0.20 1.18 x – 0.02
Florbetaben 0.72 x+0.15 0.85 x+ 0.15
Florbetapir 0.85 x+0.02 1.18 x – 0.17
SUVr
Flutemetamol 1.30 x – 0.22 0.59 x+ 0.51
Florbetaben 0.77 x+0.17 0.45 x+ 0.61
Florbetapir 1.69 x− 0.86 2.20 x – 1.33
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symptomatic patients and not only in the studies in the general popu-
lation dealing with asymptomatic subjects. Apolipoprotein E epsilon-4
genotype is a major determinant of amyloid load but we miss this data
in most patients so we cannot evaluate its influence on our population
but it is likely other variables can act on amyloid deposition rate
(Grimmer et al., 2014; Wang et al., 2017). Moreover, differences in
disease severity course may also be reflected by differences in amyloid
load among subjects with MCI (Villemagne and Rowe, 2013).
This work, moreover, is timely regarding its possible clinical ap-
plications. Firstly, it could be used to indirectly compare anti-amyloid
compounds in clinical trials based on different tracers to evaluate drug-
specific differences in target engagement and efficacy in brain amyloid
clearance, thus allowing a better understanding of their mode of action.
Moreover, if and when an anti-amyloid agent will be approved for
clinical use, availability of an approach to directly compare PET
fluorinated tracers will probably allow to streamline the eligibility
criteria evaluation and thus the treatment access.
A further possible by-product of the availability of validated, tracer-
independent cut-off and transition values that differentiate positive and
negative scans is represented by their use during resident training to
challenge the new readers with progressively difficult cases.
4.1. Study limitations
We have evaluated average tracer uptake in a volumetric ROI dis-
tributed in the whole brain without further analyzing regional differ-
ences. Some authors have reported that amyloid brain deposition in
specific regions has higher predictive value toward transition to de-
mentia or better correlate with cognitive impairment (Grothe et al.,
2017; Cho et al., 2018). This exploration was beyond the aim of the
present study although the resolution of this issue might have been
relevant to rate especially borderline cases. We plan to further explore
this issue in the future with a more homogeneous patient sample.
Another limitation is that we lacked coregistered CT in a number of
cases (50%), as only PET scans were transferred and for the oldest ones
recovery of CT was unfeasible. Indeed, it has been shown that reading
amyloid PET with coregistered CT improves correct classification
compared to PET scan alone (Curtis et al., 2015). However, we did not
observe significant differences in classification intra- and inter-observer
in the subset of patients (> 50% of the whole sample) with CT avail-
able.
Finally, APOE information was available in< 10% of all cases only.
It is therefore omitted in the demographic table and it was not used in
this study. However, we did not investigate the reason for positivity nor
the interplay with demographic variables. The semi-quantification
ranking, the visual grading and their relationship should therefore be
independent from the APOE information.
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